Is There an Association Between Quadriceps Strength and Different Markers of Fragility in Patients With Cirrhosis?
NCT ID: NCT06133127
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2023-11-20
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Main objective: To assess the association between LFI score and isometric maximal lower limb strength (quadriceps) in patients with cirrhosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study
NCT06101758
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
NCT05264051
Skeletal Muscle Parameters of Liver Cirrhosis in Non-invasive Imaging and Outcome
NCT03584204
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
NCT03142698
Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease
NCT03307408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with cirrhosis (45)
Same assessments for all patients (cirrhosis)
Frailty assessment
Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
Healthy volunteers (15 subjects)
Same assessments for all healthy volunteers
Frailty assessments
Assessments for all healthy volunteers: isometric quadriceps strength, body composition by circumference and triceps skinfold, frailty by LFI and SPPB.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Frailty assessment
Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
Frailty assessments
Assessments for all healthy volunteers: isometric quadriceps strength, body composition by circumference and triceps skinfold, frailty by LFI and SPPB.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with a diagnosis of liver cirrhosis (regardless of cirrhosis stage and etiology)
* under the care of a physician practising in the University Hospital Estaing in Clermont-Ferrand
* affiliated to the french social security system
* male subjects aged 52 to 62
* female subjects aged 42 to 60
* BMI between 20 and 30 kg/m2
* no musculoskeletal problems limiting physical activity
* level of physical activity \< 3 hours per week
* affiliated to the french social security system
Exclusion Criteria
* with hepatocellular carcinoma
* with HIV infection
* with hepatic encephalopathy grade ≥ 2
* with cognitive dysfunction
* with contraindication for physical activity
* with knee pain/knee disorders
* pregnant or breastfeeding
* under protective supervision (guardianship, curatorship, protection of the court)
* medical or surgical history deemed incompatible with the trial by the investigator
* simultaneous participation in a trial involving a drug or medical device, or period of exclusion from such a trial
* participants protected by law (under guardianship, conservatorship, or protection of the court)
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU clermont-ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01460-45
Identifier Type: OTHER
Identifier Source: secondary_id
RBHP 2023 ABERGEL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.